Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Antiphospholipid Syndrome (APS): early-phase trial registry

1 of 2 indexed Antiphospholipid Syndrome (APS) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Antiphospholipid Syndrome (APS): 2 US clinical trials tracked, 1 recruiting.

Antiphospholipid Syndrome (APS) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Chugai Pharmaceutical, running 1 of these trials.

Enrollment posture brief

Registry condition antiphospholipid-syndrome-aps

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Antiphospholipid Syndrom (th…50%
Open-enrollment share among volume-matched conditions near Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome (APS) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Antiphospholipid Syndrome (APS) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Antiphospholipid Syndrome (APS) is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Antiphospholipid Syndrome (APS) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RAY121 Drug
1 trials

US sites by state

Facility locations filed on Antiphospholipid Syndrome (APS) trials. A trial with sites in several states counts in each.

Texas 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
Maryland 1 trials
Connecticut 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Antiphospholipid Syndrome (APS) page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Antiphospholipid Syndrome (APS) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Chugai Pharmaceutical sponsors the most Antiphospholipid Syndrome (APS) trials on record, review their full trial history before evaluating a specific study. See Chugai Pharmaceutical's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Antiphospholipid Syndrome (APS) condition card totals 2 registered trials; most-linked intervention RAY121; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.